NEW YORK (GenomeWeb News) – Danish firm Nuevolution and drugmaker GlaxoSmithKline have inked a cross-licensing agreement covering DNA-tagging, synthesis, and small molecule compounds, Nuevolution said today.

Under the agreement, GSK will obtain a non-exclusive license for Nuevolution's technology, and Nuevolution will obtain a one-time license fee and a non-exclusive license under GSK's patents.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.